Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Control Intervention1: Not applicable: Not applicable
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Relapsed/Refractory B ALL patients in the age group between 1 and 25 years who have already been already Enrolled in an approved trial of CD19-directed CAR T-cell Therapy OR Counselled for and consented to receive Blinatumomab as standard of care therapy for appropriate indications
Exclusion criteria
Exclusion criteria: Not consenting to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To correlate host and disease-related biological factors with clinical profiles of patients with relapsed/refractory B-ALL prospectively treated with CD19- directed Immunotherapies (CAR T cell therapy and Blinatumomab)Timepoint: At Baseline, during the administration of the immunotherapy (CAR T cell therapy and Blinatumomab) and 1 year period post receiving CD19-directed immunotherapies | — |
Secondary
| Measure | Time frame |
|---|---|
| -To study overall response rates - CR or CRi or PR -To study survival of patients at the end of one year (RFS, PFS, EFS and OS)Timepoint: Till 1 year after completion of immunotherapy | — |
Countries
India
Contacts
Public ContactDr Swaminathan K
HBNI and Tata Memorial Hospital
Outcome results
None listed